Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
XXII 22nd Century Group Inc
- Stocks
- Healthcare
- NYSEAMERICAN: XXII
Price (delayed)
$1.25
Market cap
$2.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$173.97
Enterprise value
$7.16M
22nd Century is a plant biotechnology company focused on technology which allows it to decrease the level of nicotine in tobacco plants and modify the levels of cannabinoids in hemp/cannabis
Highlights
The company's quick ratio has surged by 187% YoY and by 25% QoQ
The company's equity has surged by 148% YoY and by 16% QoQ
The revenue fell by 24% YoY and by 12% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.xxiicentury.com
Key stats
What are the main financial stats of XXII
Market
Valuations
Earnings
Shares outstanding
2.37M
Market cap
$2.96M
Enterprise value
$7.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.11
Price to sales (P/S)
0.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
Revenue
$24.38M
Gross profit
-$2.4M
Operating income
-$13.95M
Net income
-$15.16M
EBIT
-$13.04M
EBITDA
-$11.78M
Free cash flow
-$14.46M
Per share
Balance sheet
Liquidity
EPS
-$173.97
EPS diluted
-$175.99
Free cash flow per share
-$98.8
Book value per share
$11.68
Revenue per share
$166.55
TBVPS
$108.95
Total assets
$21.67M
Total liabilities
$17.66M
Debt
$8.62M
Equity
$4.01M
Working capital
$1.56M
Debt to equity
2.15
Current ratio
1.16
Quick ratio
0.66
Net debt/EBITDA
-0.36
Margins
Efficiency
Dividend
EBITDA margin
-48.3%
Gross margin
-9.8%
Net margin
-62.2%
Operating margin
-57.2%
Return on assets
-105.5%
Return on equity
N/A
Return on invested capital
-130.2%
Return on capital employed
-111.3%
Return on sales
-53.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XXII stock price
How has the 22nd Century Group stock price performed over time
Intraday
0%
1 week
38.89%
1 month
19.05%
1 year
-99.44%
YTD
-76.46%
QTD
-13.19%
Financial performance
How have 22nd Century Group's revenue and profit performed over time
Revenue
$24.38M
Gross profit
-$2.4M
Operating income
-$13.95M
Net income
-$15.16M
Gross margin
-9.8%
Net margin
-62.2%
The net income has soared by 89% year-on-year and by 62% since the previous quarter
The net margin has soared by 86% YoY and by 57% from the previous quarter
The gross profit has soared by 73% from the previous quarter and by 72% YoY
The company's gross margin has surged by 70% QoQ and by 64% YoY
Price vs fundamentals
How does XXII's price correlate with its fundamentals
Growth
What is 22nd Century Group's growth rate over time
Valuation
What is 22nd Century Group stock price valuation
P/E
N/A
P/B
0.11
P/S
0.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
22nd Century Group's EPS has soared by 99% YoY and by 81% from the previous quarter
The company's equity has surged by 148% YoY and by 16% QoQ
The price to book (P/B) is 97% lower than the 5-year quarterly average of 3.8
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 6.7 and 90% lower than the last 4 quarters average of 0.1
The revenue fell by 24% YoY and by 12% QoQ
Efficiency
How efficient is 22nd Century Group business performance
22nd Century Group's ROS has soared by 87% YoY and by 53% from the previous quarter
The ROIC has soared by 59% YoY and by 58% from the previous quarter
The company's return on assets has surged by 52% QoQ and by 40% YoY
Dividends
What is XXII's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XXII.
Financial health
How did 22nd Century Group financials performed over time
22nd Century Group's total assets is 23% more than its total liabilities
The company's quick ratio has surged by 187% YoY and by 25% QoQ
The current ratio has soared by 78% YoY and by 6% from the previous quarter
The debt is 115% more than the equity
The company's equity has surged by 148% YoY and by 16% QoQ
The debt has contracted by 47% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.